Please assess the completion status of the following clinical trial:

Trial Title: Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Is a healthy female between 18 and 45 years of age on the day of first trial vaccination~2. Has provided signed informed consent~3. Is willing and likely to comply with the trial procedures~4. Is prepared to grant authorised persons access to their medical record~5. Willing to use acceptable contraceptive measures\* during the trial (2 weeks before and 2 weeks after the trial)~   * Heterosexually active female capable of becoming pregnant must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 2 weeks before the first vaccination until at least 2 weeks after the last. (Note: Periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal and intrauterine device or intrauterine hormone releasing system and progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, are not acceptable methods of contraception)~Exclusion Criteria:~1. Has confirmed history of Pelvic Inflammatory Disease or significant gynaecological diseases~2. Is positive for C. trachomatis (PCR)~3. Is positive for gonorrhoea (urine), HIV, Hepatitis B/C, syphilis (blood)~4. Has a positive pregnancy test~5. Has a significant active disease - such as cardiac, liver, immunological, neurological, psychiatric; or clinically significant abnormality of haematological or biochemical parameters.~6. Has BMI of 35 kg/m2 or greater~7. Is currently participating in another clinical trial with an investigational or noninvestigational drug or device~8. Has received, or plans to receive, an active immunisation within 14 days of the start of the trial or any of the immunisation visits in this trial~9. Is currently receiving treatment with immunosuppressive agents e.g. oral, inhaled, nasal or injected corticosteroids. (Topical steroids are allowed, unless applied to the IM injection site.)~10. Is using an intrauterine device~11. Has a condition which in the opinion of the investigator is not suitable for participation in the trial~12. Known or confirmed allergy to any of the vaccine constituents -

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- CTH522-CAF01 (Type: EXPERIMENTAL): CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration
- CTH522-Al(OH)3 (Type: EXPERIMENTAL): CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration
- Placebo (Type: PLACEBO_COMPARATOR): Saline for IM and In administrations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete